Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

Published

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

In this article:

You May Also Like

Investing

Rua Gold

Overview Rua Gold (CSE:RUA,OTC:NZAUF,WKN:A4010V,OTCQB:NZAUF) is a gold exploration company focused on two prolific, historic gold-producing regions in New Zealand: Hauraki Goldfield and Reefton Goldfield....

July 19, 2024

Editor's Pick

A GOP operative accused a monastery of voter fraud. Nuns fought back.

Sister Stephanie Schmidt had a hunch about what her fellow nuns would discuss over dinner at their Erie, Pennsylvania, monastery on Wednesday night. The...

October 24, 2024

Stock

Warner Bros. Discovery adds 7.2 million Max subscribers, the streamer’s largest single-quarter jump

Warner Bros. Discovery said Thursday its streaming platform Max added 7.2 million global subscribers in the third quarter. It marked the biggest quarterly growth for...

November 9, 2024

Economy

IDF kills Hezbollah commander behind brutal attack on children’s soccer field: officials

The Israel Defense Forces (IDF) announced the death of Fuad Shukr, the Hezbollah commander who was behind a drone strike that killed 12 children...

July 30, 2024

Disclaimer: wisetradeinvesting.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2024 wisetradeinvesting.com